Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “s1”

59 pharma patents match "s1" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 59
Index total 30,257
Page 2 / 3

Quick answer

This filtered view shows 59 pharmaceutical patents matching "s1" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

59 results for “s1” · 30,257 patents in full index Clear search

  1. US 11191818

    Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

    Takeda Pharmaceutical Company Limited · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  2. US 11185575

    Subcutaneous administration of ADAMTS13

    Takeda Pharmaceutical Company Limited · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  3. US 11124787

    ADAMTS13-containing compositions having thrombolytic activity

    Takeda Pharmaceutical Company Limited · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  4. US 11028392

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  5. US 10968452

    Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  6. US 10953083

    Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  7. US 10766892

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted
  8. US 10738043

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  9. US 10669320

    Mps1 and KNL1 phosphorylation system

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jun 2, 2020 · Expires May 28, 2040

    granted
  10. US 10538765

    Organic compositions to treat EPAS1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  11. US 10400239

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  12. US 10344025

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  13. WO 2019016112

    COMPOSÉS DE QUINOLÉINE À SUBSTITUTION EN POSITIONS 1, 2, 3 ET 4 UTILISÉS EN TANT QUE MODULATEURS DE S1P

    ABBVIE DEUTSCHLAND [DE] · Granted Jan 24, 2019 · Expires Jan 19, 2039

    granted
  14. US 10125128

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  15. US 10119143

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted
  16. US 10105414

    Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity

    Julius-Maximilians-Universitat Wurzburg · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  17. WO 2018083171

    COMPOSÉS SPIRO EN TANT QUE MODULATEURS DE S1P

    ABBVIE DEUTSCHLAND [DE] · Granted May 11, 2018 · Expires May 6, 2038

    granted
  18. US 9951017

    S1P3 antagonists

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  19. US 9868949

    Organic compositions to treat EPAS1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted
  20. US 9809588

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Nov 7, 2017 · Expires Nov 2, 2037

    granted
  21. US 2017174672

    FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS

    ABBVIE DEUTSCHLAND [DE] · Granted Jun 22, 2017 · Expires Jun 17, 2037

    granted
  22. US 9631193

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2017 · Expires Apr 20, 2037

    granted
  23. US 9499588

    Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof

    The Board of Regents of the University of Texas System · Granted Nov 22, 2016 · Expires Nov 17, 2036

    granted
  24. US 9133461

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 15, 2015 · Expires Sep 10, 2035

    granted